Term
|
Definition
| remove or reduce disease risk factors; ex: immunization, giving up or not starting smoking and aspirin to prevent first heart attack |
|
|
Term
|
Definition
| promote early detection of disease or precursor states; Ex: PAP or aspirin after first stroke to prevent another |
|
|
Term
|
Definition
| aimed at limiting the impact of established disease; ex: mastectomy and radiation therapy to remove breast cancer |
|
|
Term
| level 1 preventive services |
|
Definition
| providers and care systems MUST assess the need for and recommend these services to every patient. these have the highest values and are worhty of attention at every opportunity |
|
|
Term
| level 2 preventive services |
|
Definition
| providers and care systems SHOULD assess the need for and recommend these services to every patient. These have demonstrated value, although less than level 1 services, and should be provided whenever possible. |
|
|
Term
| level 3 preventive services |
|
Definition
| providers and care systems COULD recommend these services to patients, but only after careful consideration of costs and benefits. Evidence for the services is incomplete or equivocal or may have potential for harm. ...left to the judgment of the individual medical group, clinician and their patients |
|
|
Term
| level 4 preventive services |
|
Definition
| these services are not supported by evidence and should not be recommended. insufficient evidence on effectiveness, clearer evidence of lack of effectiveness or potential for harm without benefit |
|
|
Term
|
Definition
| alcohol abuse screening and counseling, aspirin chemoprophylaxis counseling, cervical cancer screening, breast cancer screening, chlamydia screening, colorectal cancer screening, hypertension screening, influenza immunization, lipid screening, pneumococcal immunization, tobacco use screening and intervention |
|
|
Term
|
Definition
| AAA screening, depression screening, folic acid chemoprophylaxis counseling, hearing screening, Hep B immunization, Zoster immunization, HPV immunization, IPV immunization, MMR immunization, Obesity screening, Osteoporosis screening, Tetanus-diptheeria immunization, varicella immunization and vision screening |
|
|
Term
|
Definition
| 19- 65 and older= identify risky or hazardous drinking and criteria for dependence and provide brief intervention |
|
|
Term
| aspirin chemoprophylaxis counseling |
|
Definition
| men 45-79 for MI and women 55-79 for stroke |
|
|
Term
|
Definition
| mammogram every one to two years for women 50-75 |
|
|
Term
| cervical cancer screening |
|
Definition
<21= no screeening
21-29= every two years
30-39= every three years
40-64= every three years after three consecutive normal Pap tests
>65= stop if no abnormal pap in 10 years |
|
|
Term
|
Definition
| all sexually active women 25 and younger and older women with new or multiple partners |
|
|
Term
| colorectal cancer screening |
|
Definition
>50 or >45 for AA and AI/AN
76-85= no screening unless significant consideractions
>86= no screening |
|
|
Term
|
Definition
| BP every 2 years if less than 120/80; every year it 120-139/80-89 |
|
|
Term
|
Definition
| annually during flu season for all individuals |
|
|
Term
|
Definition
men >34= every 5 years fasting fractionated lipid screening
Men >34 and women > 44= fasting fractionated lipid screening |
|
|
Term
| pneumococcal immunization |
|
Definition
19-64- high risk groups once and reimmunize those at risk of losing immunity after 5 years
>65= if not previously immunized or if first received more than 5 years ago and before age 64, or an immunocompromised pt. |
|
|
Term
|
Definition
| >19= establish tobacco use status for all patients; provide brief intervention |
|
|
Term
|
Definition
| men 65-75 who have ever smoked |
|
|
Term
|
Definition
| >19= routine screening; treatment and follow-up |
|
|
Term
| folic acid chemoprophylaxis counseling |
|
Definition
| 19-64= women of reproductive age to consume 400-800 mg per day |
|
|
Term
|
Definition
| >40= screening followed by counseling on the availability of hearing aid devices and making referrals for older adults |
|
|
Term
|
Definition
| routine immunization for young adults less than 40 |
|
|
Term
| Herpes zoster/shingles immunization |
|
Definition
| immunize at 60 and older in pts with no contraindications |
|
|
Term
|
Definition
| for all 11-12 year old females and catch up for F age 12-26 |
|
|
Term
|
Definition
| adults not previourly immunized against polio |
|
|
Term
|
Definition
| born during or after 9157 should have one dose; a second dose in special circumstances |
|
|
Term
|
Definition
| record height, weight and calculate body mass index at least annually |
|
|
Term
|
Definition
<65= post menopausal and determined to have a significantly increased fracture risk
>65= screened |
|
|
Term
| tetanus-diptheria immunization |
|
Definition
| one-time dose for Tdap who have not received previously or for whom vaccine status is unknown |
|
|
Term
|
Definition
| all adults without evidence of immunity; one dose followed by a second dose at least 28 days after; catch-up dose to all children, adolescents and adults who received only one dose previously |
|
|
Term
|
Definition
| >65= objective vision testing |
|
|
Term
|
Definition
| transfer of immunity as Ab which were produced by an immune animal or human to a non-immune recipient; temporary; lasts weeks to months; ex: transplancental transfer of maternal Ab |
|
|
Term
| homologous pooled human Ab |
|
Definition
| immune globulin; combining IgG Ab fraction from thousands of adult donors; primarily for postesposure prophylaxis for Hep A and measles |
|
|
Term
| Homologous human hyperimmune globulins |
|
Definition
| Ab products that contain high titers of specific Ab; dontated of humans with high levels of the Ab (other Ab in lesser quantities); against Hep B, rabies, Tetanus and varicella |
|
|
Term
| heterologous hyperimmune serum |
|
Definition
| aka antitoxin; produced in animals (horses); can result in serum sickness; Ab against only one antigen; botulism and diphteria |
|
|
Term
|
Definition
| single clone of B cells; contain Ab t only one Ag; diagnosis of certain cancers, treatment of cancer, prevention of transplant rejection, and treatmet of AI and infectious disease; ex: palivizumab is a monoconal Ab for RSV |
|
|
Term
|
Definition
| production of Ab or T cells by the patient's body after exposure to an infectious agent; made from the microorganism or its products to develop protective immunity; takes days or weeks; long lasting because of memory B and T cells |
|
|
Term
|
Definition
| altered or weakened organism that causes disease, induces an immunological response; typically lifelong immunity with a single dose or series; may cause disease; |
|
|
Term
| pts you dont give live attenuated vaccines to |
|
Definition
| HIV-infection, chronic steroids, chemotherapy, transplant patients on immunosuppressive drugs |
|
|
Term
|
Definition
| composed of the whole or part of a killed virus or bacteria; incapable of replication or causing the disease; humoral immune response |
|
|
Term
|
Definition
| acellular components such as antigenic peptides, capsular polysaccharides or cell surface protein Ag; enhanced safety profiles and increased immunogenicity to stimulat both cellular and humoral immunity; booster doses required |
|
|
Term
| pts with subunit vaccines |
|
Definition
| immunocompromised but immune response may not be adequate to protect them from the disease |
|
|
Term
|
Definition
|
|
Term
|
Definition
| commonly aded to vaccines and toxoids to increase the immunogenicity of the agent; ex: diphtheria, tetanus and pertussis; common= salts or gels |
|
|
Term
| what products require >2 doses |
|
Definition
| inactivated vaccines, toxoids, recombinant subuit vaccines, polysaccharide conjugate vaccines and live vaccines; ex: tetanus and diphtheria |
|
|
Term
| what vaccines do not induce T cell memory |
|
Definition
| unconjugated polysaccharide vaccines |
|
|
Term
| % of recipients developing protective Ab within 14 days |
|
Definition
|
|
Term
| % protected for varicell adn mmps |
|
Definition
|
|
Term
| why give a second dose for MMR? |
|
Definition
| becuase a limitd proportion 5-15% fail to respond to 1 dose |
|
|
Term
| when should you give immunizations if not on the same day? |
|
Definition
| separated by 4 weeks to reduce the risk of a reduced immune response |
|
|
Term
| what happens if given a vaccine too close together or too younga an age? |
|
Definition
| can lead to a suboptimal immunse response |
|
|
Term
| what is the earliest you can give an immunization before the age/interval |
|
Definition
|
|
Term
| why would active immunity from a live attenuated vaccine not develop? |
|
Definition
| interference from circulating Ab to the vaccine virus |
|
|
Term
|
Definition
| www.fda.gov/cber/vaers/vaers.htm |
|
|
Term
| CDC resource for common patient questions |
|
Definition
| http://www.cc.gov/vaccines/parents/index.html |
|
|
